peptide analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Largely destroyed by the Allies during the Second World War, the city was rebuilt according to the plans of the architect Auguste Perret between 1945 and 1964. Only the City Hall and the Church of Saint Joseph (107-metre high (351 ft)) were personally designed by Auguste Perret. In commending the reconstruction work UNESCO listed the city of Le Havre on 15 July 2005 as a World Heritage Site. This area of 133 hectares (330 acres) is one of the few inscribed contemporary sites in Europe. The architecture of the area is characterized by the use of precast concrete using a system of a modular frame of 6.24 m (20.5 ft) and straight lines. Another notable architectural work of the central city is that of the House of Culture built in 1982 by the Brazilian architect Oscar Niemeyer and nicknamed "the Volcano" because of the shape of the building. From 2012, this place was refurbished both inside and outside with fairly significant changes approved by the architect including greater openness to the outside of the plaza. The Notre Dame and Perrey neighbourhoods are mainly residential. Les Halles is one of the commercial hubs of the city. The Saint Francis neighborhood was also rebuilt beginning in 1950 but in a radically different architectural style: the buildings are brick and have pitched slate roofs. This is the restaurant district and the fish market.
The four substrates of this enzyme are (+)-sabinene, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. It products are (+)-sabinol, oxidised NADP+, and water. The enzyme is a monooxygenase isolated from Salvia officinalis (common sage). Its active centre is a cytochrome P450.
As a result, currant growing is making a comeback in New York, Vermont, Connecticut, California, and Oregon. However, several statewide bans still exist as of August 2021. Since the American federal ban curtailed currant production nationally for nearly a century, the fruit remains largely unknown in the United States and has yet to regain its previous popularity to levels enjoyed in Europe or New Zealand. Owing to its unique flavour and richness in polyphenols, dietary fibre and essential nutrients, awareness and popularity of blackcurrant is once again growing, with a number of consumer products entering the U.S. market.
Sources: en.wikipedia.org
=== Brand names === In May 2015, a formulation of paliperidone palmitate was approved by the US Food and Drug Administration under the brand name Invega Trinza. A similar prolonged release suspension was approved in 2016 by the European Medicines Agency originally under the brand name Paliperidone Janssen, later renamed to Trevicta. In September 2021, a newer formulation of paliperidone palmitate, Invega Hafyera, was approved by the US FDA.
The Boston keratoprosthesis is the most widely used synthetic cornea to date with over 900 procedures performed worldwide in 2008. The Boston KPro was developed at the Massachusetts Eye and Ear Infirmary under the leadership of Claes Dohlman.
Even the shell structure in the nucleus and electron cloud of oganesson is strongly impacted by relativistic effects: the valence and core electron subshells in oganesson are expected to be "smeared out" in a homogeneous Fermi gas of electrons, unlike those of the "less relativistic" radon and xenon (although there is some incipient delocalisation in radon), due to the very strong spin–orbit splitting of the 7p orbital in oganesson. A similar effect for nucleons, particularly neutrons, is incipient in the closed-neutron-shell nucleus 302Og and is strongly in force at the hypothetical superheavy closed-shell nucleus 472164, with 164 protons and 308 neutrons. Studies have also predicted that due to increasing electrostatic forces, oganesson may have a semibubble structure in proton density, having few protons at the center of its nucleus. Moreover, spin–orbit effects may cause bulk oganesson to be a semiconductor, with a band gap of 1.5±0.6 eV predicted. All the lighter noble gases are insulators instead: for example, the band gap of bulk radon is expected to be 7.1±0.5 eV.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.